Prevention of exacerbations of chronic respiratory diseases
DOI: 10.32364/2587-6821-2023-7-8-8
G.G. Prozorova1, A.A. Zaytsev2,3, V.A. Petrov4
1N.N. Burdenko Voronezh State Medical University, Voronezh, Russian Federation
2ROSBIOTECH, Moscow, Russian Federation
3N.N. Burdenko Main Military Clinical Hospital, Moscow, Russian Federation
4Obninsk Institute for Nuclear Power Engineering of the National Research Nuclear University MEPhI, Obninsk, Russian Federation
Control of virus-induced airway inflammation in patients with chronic bronchopulmonary disorders remains an urgent medical task. Managing the immune response in acute respiratory viral infections (ARVIs) in these patients is a promising area. This review summarizes the results of observational programs and initiative studies on the experience with a drug based on technologically processed antibodies in pulmonary practice. This drug is characterized by immune-mediated antiviral and antibacterial effects. The mechanism of its action implies the activation of antigen processing and presentation involving major histocompatibility complex molecules, which in turn contributes to an adequate immune response in the infectious process. Therefore, this drug can be used for treating ARVIs in patients with a high risk of unfavorable course of respiratory infections. Our findings demonstrate that this drug prevents the exacerbation of chronic bronchopulmonary disorders in ARVIs. Its inclusion in complex therapy for community-acquired pneumonia in patients with a higher risk of having resistant flora provided the completion of the treatment course without changing the antibiotic.
Keywords: chronic bronchopulmonary disorders, chronic obstructive pulmonary disease (COPD), asthma, chronic bronchitis, community-acquired pneumonia, antibiotic resistance.
For citation: Prozorova G.G., Zaytsev A.A., Petrov V.A. Prevention of exacerbations of chronic respiratory diseases. Russian Medical Inquiry. 2023;7(8):–528 (in Russ.). DOI: 10.32364/2587-6821-2023-7-8-8.
About the authors:
Galina G. Prozorova — Dr. Sc. (Med.), professor of the Department of Therapeutic Disciplines of the Institute of Continuing Professional Education, N.N. Burdenko Voronezh State Medical University; 10, Studencheskaya str., Voronezh, 394036, Russian Federation; ORCID iD 0000-0001-8675-1590.
Andrey A. Zaytsev — Dr. Sc. (Med.), Professor, Head of the Department of Pulmonology with the Course of Allergy of the Medical Institute of Continuing Education of the ROSBIOTECH; 11, Volokolamskoe road, Moscow, 125080, Russian Federation; chief pulmonologist, N.N. Burdenko Main Military Clinical Hospital; 3, Gospitalnaya sq., Moscow, 105094, Russian Federation; ORCID iD 0000-0002-0934-7313.
Vladimir A. Petrov — Dr. Sc. (Med.), Professor, Head of the Department of Infectious Diseases, Public Health, and Healthcare, Obninsk Institute for Nuclear Power Engineering of the National Research Nuclear University MEPhI; 1, Studencheskiy gorodok, Obninsk, 249040, Russian Federation; ORCID iD 0000-0002-8580-933X.
Contact information: Vladimir A. Petrov, е-mail: vapetrov1959@mail.ru.
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
Conflict of interest: Rafamin is a commercial drug produced by Scientific Production Firm MATERIA MEDICA HOLDING LLC. Patents for the technology belong to the founder of Scientific Production Firm MATERIA MEDICA HOLDING LLC. The authors reported no other conflicts of interest.
Received 14.07.2023.
Revised 08.08.2023.
Accepted 31.08.2023.
2. Садриева Е.В., Зуевская Т.В., Мартемьянова Е.А. и др. Экономическая эффективность усовершенствованной программы диспансеризации пациентов с бронхиальной астмой с коморбидными состояниями. Медицинская наука и образование Урала. 2020;21(1):34–38. [Sadrieva E.V., Zuevskaya T.V., Martem'ianova E.A. et al. Cost-effectiveness of an improved clinical examination program for patients with bronchial asthma with comorbid conditions. Medicinskaya nauka i obrazovanie Urala. 2020;21(1):34–38 (in Russ.)].
3. Jartti T., Bønnelykke K., Elenius, V. et al. Role of viruses in asthma. Semin Immunopathol. 2020;42(1):61–74. DOI: 10.1007/s00281-020-00781-5.
4. Djamin R.S., Uzun S., Snelders E. et al. Occurrence of virus-induced COPD exacerbations during four seasons. Infect Dis (Lond). 2015;47(2):96–100. DOI: 10.3109/00365548.2014.968866.
5. Stolz D., Papakonstantinou E., Grize L. et al. Time-course of upper respiratory tract viral infection and COPD exacerbation. Eur Respir J. 2019;54(4):1900407. DOI: 10.1183/13993003.00407-2019.
6. Синопальников А.И., Зайцев А.А. Современный взгляд на фармакотерапию обострений хронической обструктивной болезни легких. Лечащий врач. 2009;10:45–49. [Sinopal'nikov A.I., Zajcev A.A. Modern view on pharmacotherapy of exacerbation of chronic obstructive pulmonary disease. Lechashchij vrach. 2009;10:45–49 (in Russ.)].
7. Барабаш Е.Ю., Гвозденко Т.А., Антонюк М.В. и др. Факторы риска и особенности клеточно-фагоцитарного звена иммунной системы при легкой бронхиальной астме. Бюллетень физиологии и патологии дыхания. 2023;88:8–16. DOI: 10.36604/1998-5029-2023-88-8-16. [Barabash E.Y., Gvozdenko T.A., Antonyuk M.V. et al. Risk factors and features of the cell-phagocytic link of immune system in mild bronchial asthma. Bulletin Physiology and Pathology of Respiration. 2023;(88):8–16 (in Russ.)]. DOI: 10.36604/1998-5029-2023-88-8-16.
8. Du X.B., Ma X., Gao Y. et al. Prevalence and risk factors of respiratory viral infection in acute exacerbation of chronic obstructive pulmonary disease. Zhonghua Jie He He Hu Xi Za Zhi. 2017;40(4):263–266 (in Chinese). DOI: 10.3760/cma.j.issn.1001-0939.2017.04.004.
9. Никифоров В.В., Суранова Т.Г., Орлова Н.В. и др. Алгоритмы оказания медицинской помощи больным ОРВИ. Медицинский алфавит. 2019;2(27):6–13. DOI: 10.33667/2078-5631-2019-2-27(402)-6-13. [Nikiforov V.V., Suranova T.G., Orlova N.V. et al. Algorithms for providing medical care to patients with acute respiratory viral infections. Medical alphabet. 2019;2(27):6–13 (in Russ.)]. DOI: 10.33667/2078-5631-2019-2-27(402)-6-13.
10. Пшеничная Н.Ю., Булгакова В.А., Волчкова Е.В. и др. Обзор текущих и перспективных направлений противовирусной терапии гриппа и острых респираторных вирусных инфекций в России. Терапевтический архив. 2019;91(11):105–109. DOI: 10.26442/00403660.2019.11.000454. [Pshenichnaya N.Y., Bulgakova V.A., Volchkova E.V., et al. Review of current and future directions of antiviral therapy of influenza and acute respiratory viral infections in Russia. Therapeutic Archive. 2019;91(11):105–109 (in Russ.)]. DOI: 10.26442/00403660.2019.11.000454.
11. Tarasov S.A., Gorbunov E.A., Don E.S. et al. Insights into the Mechanism of Action of Highly Diluted Biologics. J Immunol. 2020;205(5):1345-1354. doi: 10.4049/jimmunol.2000098.
12. Петрова Н.В., Емельянова А.Г., Тарасов С.А. и др. Результаты доклинического исследования эффективности экспериментального препарата на основе технологически обработанных антител на моделях гриппа и смешанной вирусно-бактериальной инфекции. Патогенез. 2020;18(4):55–63. DOI: 10.25557/2310-0435.2020.04.55-63. [Petrova N.V., Emelianova A.G., Tarasov S.A. et al. Efficacy of an experimental drug based on technologically processed antibodies in models of influenza infection and secondary bacterial pneumonia: Results of a preclinical study. Pathogenesis. 2020;18(4):55–63 (in Russ.)]. DOI: 10.25557/2310-0435.2020.04.55-63.
13. Петрова Н.В., Емельянова А.Г., Тарасов С.А. и др. Эффективность препарата Рафамин в отношении пневмококковой инфекции (доклиническое исследование). Бюллетень экспериментальной биологии и медицины. 2023;175(5):586–590. DOI: 10.47056/0365-9615-2023-175-5-586-590. [Petrova N.V., Emelyanova A.G., Tarasov S.A. et al. Efficacy of the drug Raphamin against pneumococcal infection: a preclinical study. Bulletin of Experimental Biology and Medicine. 2023;175(5):586–590 (in Russ.)]. DOI: 10.47056/0365-9615-2023-175-5-586-590.
14. Петрова Н.В. Влияние на иммунный ответ хозяина как альтернативный подход в терапии бактериальных и вирусных инфекций. В кн.: Материал VI Междисциплинарной конференции с международным участием «Современные проблемы системной регуляции физиологических функций». М.; 2022:425. [Petrova N.V. Host-directed immunotherapy as an alternative approach to the treatment of bacterial and viral infections. In: Sixth International Interdisciplinary Conference "Modern problems in systemic regulation of physiological functions". M.; 2022:425 (in Russ.)].
15. Ганина К.К., Петрова Н.В., Тарасов С.А., Эпштейн О.И. Комбинированный препарат с антибактериальным эффектом способствует поддержанию нормофлоры кишечника. Бюллетень экспериментальной биологии и медицины. 2023;175(1):45–49. doi:10.47056/0365-9615-2023-175-1-45-49. [Ganina K.K., Petrova N.V., Tarasov S.A., Epstein O.I. The combined drug with antibacterial effect supports the intestinal normoflora. Bulletin of Experimental Biology and Medicine. 2023;175(1):45–49 (in Russ.)]. DOI: 10.47056/0365-9615-2023-175-1-45-49.
16. Хамитов Р.Ф., Никифоров В.В., Зайцев А.А., Трагира И.Н. Оценка эффективности и безопасности комплексного противовирусного препарата на основе антител в терапии взрослых больных ОРВИ. Терапевтический архив. 2022;94(1):83–93. DOI: 10.26442/00403660.2022.01.201345. [Khamitov R.F., Nikiforov V.V., Zaytsev A.A. Tragira IN. Evaluation of the efficacy and safety of a complex antiviral drug based on antibodies in the treatment of adult patients with acute respiratory viral infection. Ter Arkh. 2022;94(1):83–93 (in Russ.)]. DOI: 10.26442/00403660.2022.01.201345.
17. Яковлев С.В., Дворецкий Л.И., Петров В.А. Терапия ОРВИ у взрослых в амбулаторной клинической практике: новые возможности профилактики бактериальных осложнений (результаты наблюдательной программы РАПОРТ). Consilium Medicum. 2023;25(3):157–162. DOI: 10.26442/20751753.2023.3.202166. [Yakovlev S.V., Dvoretskiy L.I., Petrov V.A. Therapy of acute respiratory viral infections in adults in outpatient clinical practice: new opportunities for the prevention of bacterial complications (Results of the observational program RAPORT). Consilium Medicum. 2023;25(3):157–162 (in Russ.)]. DOI: 10.26442/20751753.2023.3.202166.
18. Зайцев А.А., Дворецкий Л.И., Петров В.А. Фармакотерапия ОРВИ у пациентов с хронической бронхолегочной патологией. Амбулаторный врач. Вып. № 79 от 16.06.2023. (Электронный ресурс.) URL: https://ambdoc.ru/learning/electronic-bulletin/ne-dumay-o-lekarstvakh-svysoka-79/ (дата обращения: 06.07.2023). [Zajcev A.A., Dvoreckij L.I., Petrov V.A. Pharmacotherapy of ARVI in patients with chronic bronchopulmonary pathology. Ambulatornyy vrach. Issue № 79 from 16.06.2023. (Electronic resource.) URL: https://ambdoc.ru/learning/electronic-bulletin/ne-dumay-o-lekarstvakh-svysoka-79/ (access date: 06.07.2023) (in Russ.)].
19. Мордык А.В., Пузырева Л.В., Антипова Е.П., Вербанов А.В. Клинический опыт применения препарата Рафамин у амбулаторных пациентов, перенесших коронавирусную пневмонию. Инфекционные болезни: новости, мнения, обучение. 2022;3(11):81–87. DOI: 10.33029/2305-3496-2022-11-3-81-87. [Mordyk A.V., Puzyreva L.V., Antipova E.P., Verbanov A.V. Clinical experience of Raphamin therapy in outpatients after hospital treatment of COVID-19 pneumonia. Infectious Diseases: News, Opinions, Training. 2022;11(3):81–87 (in Russ.)]. DOI: 10.33029/2305-3496-2022-11-3-81-87.
20. Хаитов Р.М. Иммунология: учебник. 4-е изд., перераб. и доп. М.: ГЭОТАР-Медиа; 2021. [Khaitov R.M. Immunology: textbook. 4th ed., revised. and additional. M.: GEOTAR-Media (in Russ.)].
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Распечатать